Johnson & Johnson, CEO, dr. Paul Stoffels, treated the effectiveness of the coronavirus vaccine compared to others already available to the public, saying it revealed ‘complete protection against death and hospitalization’.
“We conducted this study at the height of the pandemic with wide distribution in the presence of different variants,” the chief scientific officer told America’s Newsroom, referring to the variants in Brazil, South America and South Africa. .
“What we have learned is that the high percentage of efficacy against serious diseases as well as complete protection against death and hospitalization was basically the most important finding,” he added.
Johnson & Johnson said Friday that the single-shot coronavirus vaccine was 72% effective in preventing moderate to severe COVID-19 in the U.S., but dropped to 66% in a larger trial worldwide. The results stem from a phase 3 ENSEMBLE clinical trial, in which 43 783 participants were involved.
The shot was found to be 66% effective in preventing moderate to severe diseases in Latin America, and 57% effective in South Africa at 28 days after vaccination. When the company only looked at serious cases, the protection increased to 85%.
FAUCI S UK UK COVID-19 TRIBES CAN ‘CAUSE MORE DAMAGE,’ WE WILL TEST FOR SUBSTANCE EFFECT
The coronavirus vaccine developed by Pfizer Inc. and partner BioNTech SE, were more than 90% effective in the first 94 subjects infected with the new coronavirus and developing at least one symptom, the companies announced in November.
Moderna said in November that the experimental vaccine was 94.5% effective in preventing COVID-19, based on interim data from a late-stage clinical trial.
Stoffels noted that ‘90% of the people in our study were people with the South African tribe, and it is known that it is very resistant to many treatments, but also to the current vaccinations. ‘
“Therefore, the finding we find here is very relevant that we can still protect regardless of age, risk factor, ethnicity, geography and stress,” he went on to point out that the single-dose vaccine Johnson & Johnson is a very important role ‘will play. in the fight against the pandemic in the world. ‘
The J&J vaccine differs from the currently approved samples in the US because it requires a single shot, as opposed to two doses, and it can be stored in warmer temperatures than the others.
The company suggested that the shot be safe and well tolerated; 9% of the participants in the trial developed a fever and there were no serious allergic reactions.
Stoffels told “America’s Newsroom” on Wednesday that the company plans to file an emergency use authorization (EUA) in the U.S. this week and submit the results of a clinical trial. The company said it would be ready to ship immediately after authorization.
‘The FDA will take a few weeks to review it [the data] and hopefully we will get the authorization for emergency use in early March, in that time frame, ‘Stoffels said.
In August, Johnson & Johnson announced that it would supply 100 million doses of coronavirus vaccine to the United States in an agreement with the government worth more than $ 1 billion.
On Wednesday, host Bill Hemmer asked Stoffels whether the US would “get 100 million Johnson & Johnson shots by the summer?”
“Right,” he replied, noting that “100 million shots means 100 million people.”
“It’s going to make a big difference in the US for many, many people to be protected from the disease, but also for the country to become normal again,” Stoffels continued.
“I think we will make a significant contribution to getting the US pandemic under control in the next few months.”
CLICK HERE TO GET THE FOX NEWS APP
FOX News, Alexandria Hein and Kayla Rivas and FOX Business, Daniella Genovese, contributed to this report.